EGF could rapidly increase splicing of XBP1s mRNA in breast cancer cells, and pre-treating cells with the EGFR inhibitor, erlotinib, blocked EGF-induction of spliced XBP1 mRNA 28. Here, XBP1 is linked to breast cancer.